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M. I. POLKEY*, P. 0. G. WILSON AND P. J. REES 
Departments of Medicine and Pathology, Guy’s Hospital, St. Thomas Street, London SE1 9RT, U.K. 
Pneumonitis is a serious adverse effect of amiodarone therapy, which is related to the average daily dose. A 
case of pneumonitis is described which developed after exposure to a low dose of amiodarone. This challenges 
the concept that low dose amiodarone therapy is safe. 
Introduction 
Amiodarone pneumonitis is a well documented 
adverse drug effect. The risk of developing puhnon- 
ary toxicity has been reported to be dose-dependent 
(1,2). We report a case of amiodarone-induced pneu- 
monitis which occurred after a very small exposure, 
and after the drug had been discontinued. 
Case Report 
A 73-year-old man with non-insulin dependent 
diabetes was admitted to the Intensive Care Unit 
with seizures, following recurrent hypoglycaemic epi- 
sodes related to oral hypoglycaemic therapy. He was 
a non-smoker with no history of chest or connective 
tissue disease. Atria1 fibrillation reverted to sinus 
rhythm after a single loading dose of amiodarone 
(1200 mg). The drug was continued at 200 mg daily 
for 29 days and for a further 29 days at 100 mg daily; 
in total he received 9.9 g of amiodarone. His serum 
creatinine and liver function tests were normal. When 
amiodarone was stopped he had no pulmonary 
symptoms and a normal chest X-ray. 
Three weeks after stopping therapy, he reattended 
with a short history of malaise, severe dyspnoea 
and a non-productive cough. He had developed 
finger-clubbing and showers of fine, late inspiratory 
crackles were audible at the lung bases. A chest X-ray 
(Plate 1) showed bilateral small-nodular shadowing, 
and arterial blood-gas tensions were PO, 4.9 kPa and 
PCO, 3.67 kPa whilst breathing room air. Lung 
function tests were not done at presentation because 
of the severity of his condition. Bronchoalveolar 
lavage showed numerous lipid-laden macrophages. 
Transbronchial biopsy (Plate 2) showed bronchiolitis 
Received 24 June 1994 and accepted in revised form 24 August 1994. 
*Author to whom correspondence should be addressed at: Depart- 
ment of Thoracic Medicine, Kings College School of Medicine, 
Bessemer Road, London SE5 9PJ, U.K. 
0954-611 l/95/030233+03 $08.0010 
obliterans organizing pneumonia (BOOP), character- 
ized by buds of fibrous granulation tissue (Masson 
bodies) extending into intra-alveolar air spaces. 
These appearances have been described in association 
with amiodarone pneumonitis (3). Bilateral pneumo- 
thoraces followed the transbronchial biopsy which 
resolved with intercostal tube drainage. 
He received prednisolone, initially 30 mg and then 
20 mg daily, for a total of 10 weeks. His symptoms 
and signs resolved and there was complete clearing of 
the chest X-ray. He remained symptom free with a 
normal chest X-ray when seen 2 months after 
stopping prednisolone. His spirometry then showed 
FEV,/FVC of 2.7/3.1 1(105% and 86% respectively of 
predicted values). 
Discussion 
Pneumonitis is arguably the most serious side effect 
of amiodarone therapy: over 400 cases have been 
reported since the original description in 1980 (4). 
Reported mortality rates are between 9.1 and 22% 
(1,2,5). The incidence of pneumonitis in the largest 
prospective study was 3.5% after 1 yr (2) rising to 
9.1% after 5 yr in patients receiving high doses (5). 
In that study, no case of pneumonitis occurred in 
patients treated with up to 300 mg daily. The vast 
majority of published cases have used daily doses 
greater than 400 mg. This is in contrast to other side 
effects, such as skin discolouration, which are 
thought to relate purely to the cumulative dose. 
Causality may only be inferred rather than proven 
from a single case, but our patient had a clinical and 
radiological picture of pneumonitis which resembled 
that seen after exposure to higher doses of amio- 
darone. BOOP is a recognized histological finding in 
amiodarone pneumonitis (3) and conversely, amio- 
darone toxicity is recognized as a cause of clinical 
BOOP (6). No other recognized cause of BOOP was 
present in our patient. 
0 1995 W. B. Saunders Company Ltd 
234 M. I. Polkey et al. 
Plufe I AP Chest X-ray showing bilateral interstial sh; adowing. An intercostal drain is visible on the left. 
Plate 2 Transbronchial biopsy showing buds of fibrous granulation tissue extending into intra-alveolar air spaces 
(H & E stain, medium power.) 
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Amiodarone, in low dose (i.e. up to 200 mg daily), 
is considered by some to be virtually free of serious 
side effects (7,8). The concept of a safe low dose is 
further supported by a study which demonstrated 
that rats could be given up to 175 mg kg ~ ’ day - ’ of 
amiodarone without developing pulmonary toxicity 
(9). Consequently, amiodarone in low dose is now 
advocated for treatment of atria1 fibrillation, in 
addition to ventricular arrhythmias (10). 
However in a recent study, a significant decline in 
diffusion capacity was seen in 29% of patients, taking 
up to 400 mg of amiodarone daily after 47 months 
(11). There is one previous case of interstial pneu- 
monitis (with similar histological findings) in a 
patient receiving only 200 mg daily of amiodarone 
w-9. 
Our patient developed amiodarone pneumonitis 
after a cumulative dose of 9.9 g of drug, with daily 
dose not exceeding 200 mg, and after the drug had 
been discontinued. This has not been previously 
described and further challenges the notion of a safe 
low dose of amiodarone. We conclude that serious 
side effects of amiodarone can occur even at low 
dosages. 
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